Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Shares of Humana Inc. rallied 3.94% to $247.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.09% to 5,963.60 and the Dow ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

The performance and reduced forecast led to a ... The warning about healthcare costs dragged other insurer stocks, with Humana (HUM), CVS Health (CVS), and Elevance Health (ELV) also among the ...

This was the stock's second consecutive day of losses.

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.